Amundi
NBIX icon

Amundi’s Neurocrine Biosciences NBIX Stock Holding History

Amundi’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.2M Buy
220,463
+16,826
+8% +$2.5M 0.01% 668
2026
Q1 		$26.8M Buy
203,637
+37,287
+22% +$4.95M 0.01% 715
2025
Q4 		$23.6M Sell
166,350
-63,913
-28% -$9.26M 0.01% 781
2025
Q3 		$32.1M Buy
230,263
+11,068
+5% +$1.5M 0.01% 649
2025
Q2 		$28.4M Sell
219,195
-11,992
-5% -$1.38M 0.01% 650
2025
Q1 		$23.8M Sell
231,187
-30,673
-12% -$3.89M 0.01% 683
2024
Q4 		$36.3M Sell
261,860
-394,835
-60% -$48.8M 0.01% 624
2024
Q3 		$73.3M Buy
656,695
+265,382
+68% +$36.4M 0.03% 471
2024
Q2 		$54.1M Buy
391,313
+29,641
+8% +$4.06M 0.02% 503
2024
Q1 		$47.9M Buy
361,672
+21,458
+6% +$2.93M 0.02% 530
2023
Q4 		$45.5M Buy
340,214
+34,820
+11% +$4.01M 0.02% 546
2023
Q3 		$34.5M Sell
305,394
-884,632
-74% -$93.2M 0.02% 586
2023
Q2 		$112M Sell
1,190,026
-31,815
-3% -$3.11M 0.06% 333
2023
Q1 		$125M Buy
1,221,841
+298,475
+32% +$31.1M 0.07% 299
2022
Q4 		$102M Buy
923,366
+106,554
+13% +$12.5M 0.06% 342
2022
Q3 		$88.7M Buy
816,812
+751,542
+1,151% +$76.3M 0.05% 364
2022
Q2 		$6.15M Sell
65,270
-581
-0.9% -$53.6K ﹤0.01% 876
2022
Q1 		$6.49M Sell
65,851
-73,571
-53% -$6.24M ﹤0.01% 916
2021
Q4 		$11M Buy
139,422
+1,527
+1% +$140K 0.01% 816
2021
Q3 		$13.2M Buy
137,895
+16,109
+13% +$1.52M 0.01% 777
2021
Q2 		$11.9M Buy
+121,786
New +$11.7M 0.01% 798

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Amundi's NBIX Position: Q2 2026 in Review

Amundi increased its Neurocrine Biosciences (NBIX) stake by 8.3% in Q2 2026, buying an estimated $2.5M and bringing the position to 220,463 shares worth $37.2M. The position accounts for 0.01% of the portfolio, ranked #668.

Amundi first reported a position in NBIX in Q2 2021 and has held it in 21 quarters since. The position peaked at $125M in Q1 2023. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Amundi held 220,463 shares of Neurocrine Biosciences worth $37.2M as of Q2 2026.
  • Amundi bought 16,826 Neurocrine Biosciences shares in Q2 2026, an estimated $2.5M.
  • Neurocrine Biosciences made up 0.01% of Amundi's portfolio in Q2 2026, its #668 holding.
  • Amundi first reported a position in Neurocrine Biosciences in Q2 2021 and has held it in 21 quarters since.
  • Amundi's Neurocrine Biosciences position peaked at $125M in Q1 2023.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.